Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories

Share:

 
 

East Texas Clinical Trials

Texas Oncology cancer centers in east Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the east Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the east Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in a Clinical Trial

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the east Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the east Texas area and talk to you doctor to determine which clinical trial is right for you.

Anal Cancer

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Biliary Cancer

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View

Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View

Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View

Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Bladder Cancer

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Bone Mets

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Tyler

Phase: I/II

Brain Cancer

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Breast Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CONTESSA2: Ph2 HER2- HR+ BC View

Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CONTESSA2: Ph2 HER2- HR+ BC View

Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CONTESSA2: Ph2 HER2- HR+ BC View

Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 IMMU-132 HR+, HER2- mBC View

Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 IMMU-132 HR+, HER2- mBC View

Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 IMMU-132 HR+, HER2- mBC View

Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 2 rib + non-ster AIs HR+ HER2- aBC View

Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph 2 rib + non-ster AIs HR+ HER2- aBC View

Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph 2 rib + non-ster AIs HR+ HER2- aBC View

Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Cervical Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Colon Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Endometrial Cancer

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: III

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Epithelial Carcinomas

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Longview Cancer Center

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Canton

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Tyler

Esophageal Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: III

Essential Thrombocythemia

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Tyler

Phase: III

Fallopian Tube Cancer

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: III

Gall Bladder Cancer

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Gastric Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Head and Neck Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Kaposi's Sarcoma

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Tyler

Phase: I/II

Kidney Cancer

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Leukemia

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View

Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View

Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View

Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Liver Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Lung Cancer

Title: LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II/III

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Lymphomas

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 JCAR017 R/R NHL View

Description: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-017007)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 JCAR017 R/R NHL View

Description: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-017007)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Canton

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Malignant Adenoma

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Tyler

Phase: I/II

Melanoma

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I/II

Myelodysplastic Syndrome

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I/II

Myelofibrosis

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: III

Myelomas

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph3 R/R MM (DREAMM 3) View

Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R MM (DREAMM 3) View

Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R MM (DREAMM 3) View

Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: III

Ovarian Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Pancreatic Cancer

Title: Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Title: Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Penile Cancer

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Peritoneal Cancer

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: III

Prostate Cancer

Title: A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE) View

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Rectal Cancer

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Renal Cancer

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Sarcoma

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I/II

Solid Tumors

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Testicular Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Thyroid Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Urothelial Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Uterine Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Vaginal Cancer

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Vulvar Cancer

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Texas Oncology-Canton

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Canton

Title: Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View

Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: IV

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CONTESSA2: Ph2 HER2- HR+ BC View

Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 IMMU-132 HR+, HER2- mBC View

Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 2 rib + non-ster AIs HR+ HER2- aBC View

Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View

Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II/III

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 JCAR017 R/R NHL View

Description: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-017007)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Canton

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: III

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: IV

Title: Ph3 R/R MM (DREAMM 3) View

Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I/II

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: IV

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Canton

Phase: I/II

Texas Oncology-Longview Cancer Center

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE) View

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Longview Cancer Center

Title: Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View

Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CONTESSA2: Ph2 HER2- HR+ BC View

Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 IMMU-132 HR+, HER2- mBC View

Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 2 rib + non-ster AIs HR+ HER2- aBC View

Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View

Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph3 R/R MM (DREAMM 3) View

Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Texas Oncology-Paris

Title: LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Paris

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Texas Oncology-Tyler

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Tyler

Title: Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View

Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CONTESSA2: Ph2 HER2- HR+ BC View

Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 IMMU-132 HR+, HER2- mBC View

Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 2 rib + non-ster AIs HR+ HER2- aBC View

Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View

Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 JCAR017 R/R NHL View

Description: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-017007)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: III

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph3 R/R MM (DREAMM 3) View

Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Tyler

Phase: I/II

No Phase

Title: A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE) View

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Longview Cancer Center

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Canton

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Tyler

Title: Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Title: Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Canton

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase I

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/1b TNBC, Ovarian View

Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Phase I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH1b/2 Nirap Combo Tx for mCRPC View

Description: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 MRTX849 Solid Tumors KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Phase II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CONTESSA2: Ph2 HER2- HR+ BC View

Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CONTESSA2: Ph2 HER2- HR+ BC View

Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CONTESSA2: Ph2 HER2- HR+ BC View

Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 2 rib + non-ster AIs HR+ HER2- aBC View

Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph 2 rib + non-ster AIs HR+ HER2- aBC View

Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph 2 rib + non-ster AIs HR+ HER2- aBC View

Description: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View

Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View

Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View

Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 JCAR017 R/R NHL View

Description: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-017007)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 JCAR017 R/R NHL View

Description: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-017007)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 BGB-3111 Ibrut intolerant CLL/SLL View

Description: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: II

Phase II/III

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II/III

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Phase III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure View

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View

Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View

Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View

Description: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 IMMU-132 HR+, HER2- mBC View

Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 IMMU-132 HR+, HER2- mBC View

Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 IMMU-132 HR+, HER2- mBC View

Description: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: III

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 R/R MM (DREAMM 3) View

Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R MM (DREAMM 3) View

Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R MM (DREAMM 3) View

Description: 207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: